Recent submissions
Now showing items 1-20 of 734
-
Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.
(2017-08-19)BACKGROUND: While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to ... -
Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis.
(2015-06-05)To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-analysis of published case-control studies. Of ... -
Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
(2017-05-10)Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and ... -
Genome-wide homozygosity signature and risk of Hodgkin lymphoma.
(2015-01)Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is associated ... -
Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution.
(2016-09-12)1.We have previously described C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as cell permeable inhibitors of the KDM4 and KDM5 subfamilies of JmjC histone lysine demethylases. 2.Although exemplar compound 1 ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
(2017-08-15)AIM: To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy. METHODS: Individual patient data were pooled from three randomised phase ... -
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
(2017-08-22)Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients ... -
Response to comment by G. Borasi.
(2017-08-16) -
David Cosgrove OBITUARY
(2017-08-11) -
Investigation of In Vivo skin stiffness anisotropy in breast cancer related lymphoedema.
(2016-01)There is a limited range of suitable measurement techniques for detecting and assessing breast cancer related lymphoedema (BCRL). This study investigated the suitability of using skin stiffness measurements, with a particular ... -
Treating cancer with selective CDK4/6 inhibitors.
Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ... -
Treating cancer with selective CDK4/6 inhibitors.
(2016-07)Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...
